
Journal of Medicinal Chemistry p. 1273 - 1279 (1992)
Update date:2022-08-04
Topics:
Lawrence
Venepalli
Appell
Goswami
Logan
Tomczuk
Yanni
The synthesis of unsymmetrical naphth[2,3-d]imidazolium and bridged naphth[2,3-d]imidazolium derivatives and their substance P (SP) antagonist activity are described. All compounds were evaluated for their ability to displace SP from neurokinin-1 (NK-1) receptor sites using standard receptor binding methodology (rat forebrain membrane). 1,3-Diethyl-2-[3-(1,3-dihydro- 1,3,3-trimethyl-2H-indol-2-ylidene)-1-propenyl]-1H-naphth[2,3-d]imidazolium chloride (7a), a representative compound in this series, was further evaluated for SP antagonist activity in a guinea pig ileum contractility assay. In vivo SP antagonist activity of 7a was demonstrated using SP-induced salivation and paw edema models performed in rats.
View MoreShandong united-rising pharmaceutical cooperation.,ltd.
Contact:008653187965009
Address:171No., Jing5 Road, Shizhong District, Jinan, China
Ji'nan Orgachem Pharmaceutical Co.,Ltd
Contact:+86-531-82687810
Address:Jinan
Anqing World Chemical Co., Ltd.
Contact:+86-556-5800026
Address:Daguan Economic Development Zone of circular economy industrial park Anqing City Anhui province
Contact:+86-13236304423
Address:heping street NO.828,weifang city,shandong province,china
Wuxi Pharma-Trading Import & Export Co.,Ltd.
Contact:+86-510-82304590 82716390
Address:Room 523,Youzu Alliance Building,No.88 Renmin Zhonglu,Wuxi,Jiangsu,China
Doi:10.3906/kim-1110-43
(2012)Doi:10.1002/ejoc.201200158
(2012)Doi:10.1016/j.jorganchem.2012.05.023
(2012)Doi:10.1039/C5RA27624A
(2016)Doi:10.1021/jacs.0c02721
(2020)Doi:10.3109/14756366.2011.597748
(2012)